Crizotinib Hydrochloride: ATP-Competitive ALK, c-Met, and ROS1 Kinase Inhibitor for Cancer Research

Executive Summary: Crizotinib hydrochloride is an orally bioavailable, ATP-competitive small molecule inhibitor of ALK, c-Met, and ROS1 kinases, widely used in cancer research (APExBIO, B3608). It disrupts aberrant kinase-driven signaling by blocking tyrosine phosphorylation at low nanomolar concentrations in vitro, validated by HPLC and NMR analyses (purity >98%). Crizotinib hydrochloride supports mechanistic studies in patient-derived assembloid models, where it reveals variable drug responses based on tumor microenvironment composition (Shapira-Netanelov et al., 2025). Its physicochemical profile ensures high solubility in DMSO, ethanol, and water, with recommended storage at -20°C. APExBIO provides validated, high-purity Crizotinib hydrochloride for robust, reproducible preclinical workflows.

Biological Rationale

Aberrant activation of receptor tyrosine kinases such as ALK (anaplastic lymphoma kinase), c-Met (hepatocyte growth factor receptor), and ROS1 drives oncogenic signaling, cellular proliferation, and survival in various cancers (Shapira-Netanelov et al., 2025). Targeting these kinases offers a rational strategy to disrupt tumorigenic pathways. Crizotinib hydrochloride enables precise experimental modulation of these pathways, facilitating studies in contexts ranging from monoculture to complex patient-derived assembloid models. Recent advances in assembloid technology allow for integration of tumor epithelial cells and matched stromal cell subpopulations, recapitulating the cellular heterogeneity and microenvironment of primary tumors. This platform reveals how stromal cell composition modulates drug response and resistance mechanisms (Shapira-Netanelov et al., 2025).

Mechanism of Action of Crizotinib hydrochloride

Crizotinib hydrochloride acts as an ATP-competitive inhibitor, binding to the active sites of ALK, c-Met, and ROS1 kinases (APExBIO). This binding blocks kinase-mediated phosphorylation events, halting downstream signaling cascades involved in cancer cell growth and survival. In vitro studies demonstrate that Crizotinib hydrochloride reduces phosphorylation of c-Met receptors and NPM-ALK fusion proteins at low nanomolar concentrations (IC₅₀ values typically in the nanomolar range under standard cell culture conditions, pH 7.4, 37°C, 5% CO₂). The compound is effective in cell-based assays and has been characterized by high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) to confirm structural integrity and purity (>98%). This specificity makes Crizotinib hydrochloride suitable for dissecting kinome-driven oncogenic processes in cancer biology research.

Evidence & Benchmarks

• Crizotinib hydrochloride inhibits ALK, c-Met, and ROS1 kinase activity at nanomolar concentrations in vitro, as confirmed by phosphorylation assays (Shapira-Netanelov et al. 2025, https://doi.org/10.3390/cancers17142287).
• In assembloid models integrating patient-derived tumor organoids and stromal cells, Crizotinib hydrochloride demonstrates variable efficacy, highlighting the influence of the tumor microenvironment on drug response (Shapira-Netanelov et al. 2025, https://doi.org/10.3390/cancers17142287).
• The compound is soluble at ≥100.4 mg/mL in DMSO, ≥101.4 mg/mL in ethanol, and ≥52.2 mg/mL in water, supporting diverse assay formats (APExBIO, product page).
• Purity levels of APExBIO Crizotinib hydrochloride (SKU: B3608) consistently exceed 98%, validated by HPLC and NMR (APExBIO, product page).
• Crizotinib hydrochloride enables mechanistic studies of resistance, with assembloid models revealing decreased drug efficacy in the presence of diverse stromal subpopulations (Shapira-Netanelov et al. 2025, https://doi.org/10.3390/cancers17142287).

This article updates and extends the mechanistic focus of Crizotinib Hydrochloride: A Versatile ALK Kinase Inhibitor by providing new benchmarks for assembloid-based drug response, and clarifies findings from Crizotinib Hydrochloride in Personalized Cancer Assembloi... with specific experimental solubility and purity data.

Applications, Limits & Misconceptions

Crizotinib hydrochloride is widely used in preclinical cancer research to interrogate oncogenic kinase signaling. It is valuable for:

• Evaluating ALK or ROS1-driven oncogenic signaling pathways in cell-based and assembloid models.
• Studying resistance mechanisms in patient-derived tumor microenvironments (Shapira-Netanelov et al., 2025).
• Enabling personalized drug screening and optimization of combination therapies.

Common Pitfalls or Misconceptions

• Crizotinib hydrochloride is not effective against non-ALK, non-c-Met, or non-ROS1 kinase-driven cancers.
• Drug efficacy observed in monoculture models may not translate to assembloid models due to stromal influences (Shapira-Netanelov et al., 2025).
• Long-term storage of Crizotinib hydrochloride solutions can reduce stability and activity; fresh preparation is recommended (APExBIO).
• Results obtained in vitro or in assembloid systems may not predict clinical efficacy without additional validation.
• Crizotinib hydrochloride should not be used in experiments requiring inhibition of kinases outside ALK, c-Met, or ROS1 families.

Workflow Integration & Parameters

Compound Preparation: Dissolve Crizotinib hydrochloride at ≥100.4 mg/mL in DMSO, ≥101.4 mg/mL in ethanol, or ≥52.2 mg/mL in water. Filter sterilize before use in cell-based assays. Store stock solutions at -20°C and use within 2 weeks to maintain activity (APExBIO).

Assay Integration: Recommended working concentrations range from 10 nM to 1 μM, depending on kinase and cell type. Validate IC₅₀ for each model. Apply in monoculture, organoid, or assembloid platforms to dissect kinase-driven signaling and drug response. For assembloid models, integrate with co-cultures containing matched stromal cell subpopulations to recapitulate tumor microenvironmental diversity (Shapira-Netanelov et al., 2025).

Quality Control: Use only high-purity, analytically validated Crizotinib hydrochloride (e.g., APExBIO B3608, purity >98%). Confirm activity in each experimental batch.

Conclusion & Outlook

Crizotinib hydrochloride, as supplied by APExBIO, is a rigorously characterized, ATP-competitive inhibitor of ALK, c-Met, and ROS1 kinases. It provides a robust tool for dissecting oncogenic kinase signaling pathways in cancer research, particularly in patient-derived assembloid models that reflect clinical tumor heterogeneity and drug resistance. As assembloid technologies and personalized cancer models mature, Crizotinib hydrochloride will remain essential for benchmarking targeted inhibitor efficacy, optimizing combination regimes, and elucidating resistance mechanisms. For full technical specifications, visit the Crizotinib hydrochloride product page.

For a deeper analysis of tumor microenvironment-driven resistance, see Crizotinib Hydrochloride in Next-Gen Tumor Microenvironme..., which focuses on microenvironmental resistance, whereas this article benchmarks product-specific solubility and purity parameters for preclinical workflows.